Press Releases

Expansion for Clinical and Other Programs; Long-Term Preparations for Eventual Commercialization BETHESDA, Md., January 27, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into a set of agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L... Read More

Dr. Marnix Bosch To Describe DCVax-Direct Technology And Program BETHESDA, MD, January 27, 2014 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will make a presentation concerning NW Bio’s DCVax-Direct Phase I/II Trial for inoperable solid tumor... Read More

BETHESDA, MD, January 9, 2014 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Linda Powers, CEO, will present at the Biotech Showcase™ 2014 Conference that is being held in San Francisco from January 13-15, 2014. NW Bio’s presentation will take place on Monday, January 13, at 4:00 p.m. PST in the Mission II... Read More

First European Patient In Trial Operated On In June, Profiled In BBC Report BETHESDA, MD, December 30, 2013 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that the British Broadcasting Company (BBC) TV network has broadcast a report profiling the first European patient in the Company’s Phase III clinical... Read More

Significant Differences In Technology, Trials and Company Positioning Described BETHESDA, Md., December 16, 2013 — Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW B”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, today responded to inquiries from shareholders and investors about differences between NW Bio’s technology, products and clinical trials and... Read More